Oleksyszyn J, Boduszek B, Kam C M, Powers J C
School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta 30332-0400.
J Med Chem. 1994 Jan 21;37(2):226-31. doi: 10.1021/jm00028a004.
A series of new peptidyl (alpha-aminoalkyl)phosphonate diphenyl esters containing the 4-amidinophenyl group were synthesized and tested as irreversible inhibitors for thrombin and other trypsin-like enzymes. These phosphonates irreversibly inhibited several coagulation enzymes and trypsin. Boc-D-Phe-Pro-(4-AmPhGly)P(OPh)2 is the best human thrombin inhibitor in the series with a k(obs)/[I] value of 11,000 M-1 s-1, and it inhibits thrombin more than 5-fold more effectively than the other enzymes tested. Z-(4-AmPhGly)P(OPh)2 is the best inhibitor for plasma kallikrein with a k(obs)/[I] value of 18,000 M-1 s-1. Generally, the (4-AmPhGly)P(OPh)2 derivatives are better inhibitors of thrombin and trypsin than the corresponding (4-AmPhe)P(OPh)2 derivatives which contain an extra CH2 separating the amidinophenyl group from the peptide backbone. The amidino phosphonates did not inhibit acetylcholinesterase and were chemically stable in neutral buffers. In addition, the inhibited trypsin derivative did not regain any enzyme activity after removal of excess inhibitor and incubation in a pH 7.5 buffer for 1 day. Boc-D-Phe-Pro-(4-AmPhGly)P(OPh)2 and D-Phe-Pro-(4-AmPhe)P(OPh)2 prolonged the prothrombin time ca. 2-fold and prolonged the activated partial thromboplastin time ca. 3-4-fold in human plasma at concentrations of 63 and 125 microM, respectively. The novel amidine-containing peptidyl phosphonates reported here are thus effective anticoagulants in vitro, and they may have utility for use in vivo.
合成了一系列含有4-脒基苯基的新型肽基(α-氨基烷基)膦酸二苯酯,并作为凝血酶和其他类胰蛋白酶的不可逆抑制剂进行了测试。这些膦酸酯不可逆地抑制了几种凝血酶和胰蛋白酶。Boc-D-Phe-Pro-(4-AmPhGly)P(OPh)₂是该系列中最佳的人凝血酶抑制剂,k(obs)/[I]值为11,000 M⁻¹ s⁻¹,其抑制凝血酶的效果比其他测试酶高出5倍以上。Z-(4-AmPhGly)P(OPh)₂是血浆激肽释放酶的最佳抑制剂,k(obs)/[I]值为18,000 M⁻¹ s⁻¹。一般来说,(4-AmPhGly)P(OPh)₂衍生物比相应的(4-AmPhe)P(OPh)₂衍生物是更好的凝血酶和胰蛋白酶抑制剂,后者在脒基苯基与肽主链之间多一个CH₂。脒基膦酸酯不抑制乙酰胆碱酯酶,且在中性缓冲液中化学稳定。此外,被抑制的胰蛋白酶衍生物在去除过量抑制剂并在pH 7.5缓冲液中孵育1天后,未恢复任何酶活性。Boc-D-Phe-Pro-(4-AmPhGly)P(OPh)₂和D-Phe-Pro-(4-AmPhe)P(OPh)₂在人血浆中浓度分别为63和125 μM时,使凝血酶原时间延长约2倍,活化部分凝血活酶时间延长约3 - 4倍。因此,本文报道的新型含脒基肽基膦酸酯在体外是有效的抗凝剂,并且可能在体内具有应用价值。